OPTHEA LTD (SP.ADR/8) Market Cap ($512.99 Million)
Market Cap & Net Worth: OPTHEA LTD (SP.ADR/8) (UKJ2)
OPTHEA LTD (SP.ADR/8) market cap. OPTHEA LTD (SP.ADR/8) (F:UKJ2) has a market capitalization of $512.99 Million (€438.79 Million) as of October 31, 2026. Listed on the F stock exchange, this Germany-based company holds position #11700 globally and #1318 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OPTHEA LTD (SP.ADR/8)'s stock price €3.00 by its total outstanding shares 170997272 (171.00 Million).
OPTHEA LTD (SP.ADR/8) Market Cap History (2020–2026)
OPTHEA LTD (SP.ADR/8) market cap history from 2020 to 2026. Data shows change from $1.81 Billion to $599.74 Million (-21.21% CAGR). Check OPTHEA LTD (SP.ADR/8) (UKJ2) share price today for real-time trading data and today's change.
OPTHEA LTD (SP.ADR/8) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OPTHEA LTD (SP.ADR/8)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see OPTHEA LTD (SP.ADR/8) cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
23989.65x
OPTHEA LTD (SP.ADR/8)'s market cap is 23989.65 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $923.60 Million | $90.68K | -$92.82 Million | 10184.95x | N/A |
| 2023 | $523.77 Million | $108.00K | -$142.52 Million | 4849.76x | N/A |
| 2024 | $735.68 Million | $125.00K | -$220.24 Million | 5885.46x | N/A |
| 2025 | $599.74 Million | $25.00K | -$162.79 Million | 23989.65x | N/A |
Competitor Companies of UKJ2 by Market Capitalization
Companies near OPTHEA LTD (SP.ADR/8) in the global market cap rankings as of October 31, 2026. See UKJ2 net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to OPTHEA LTD (SP.ADR/8) by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of OPTHEA LTD (SP.ADR/8) (2020–2026)
Market capitalization of OPTHEA LTD (SP.ADR/8) from 2020 to today. Between 2020 and today, OPTHEA LTD (SP.ADR/8)'s market cap moved from $1.81 Billion to $ 599.74 Million, with a yearly change of -21.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €599.74 Million | 0.00% |
| 2025 | €599.74 Million | -18.48% |
| 2024 | €735.68 Million | +40.46% |
| 2023 | €523.77 Million | -43.29% |
| 2022 | €923.60 Million | -29.47% |
| 2021 | €1.31 Billion | -27.62% |
| 2020 | €1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of OPTHEA LTD (SP.ADR/8) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $512.99 Million USD |
| MoneyControl | $512.99 Million USD |
| MarketWatch | $512.99 Million USD |
| marketcap.company | $512.99 Million USD |
| Reuters | $512.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OPTHEA LTD (SP.ADR/8)
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more